Gapping up
In reaction to earnings/guidance:
- SEDG +12.1%, ZI +12%, MYGN +10.2%, IGT +8.1%, OTTR +7.5%, CLR +6.9% (also resumes share repurchase program), UIS +6.5%, HLIT +5.8%, BP +5.7%, STLA +5.2%, ATKR +5%, BCC +4.6%, UAA +4.5%, COLM +4%, KMT +3.7% (also authorizes $200 mln share repurchase program), PBI +3.4%, MTRN +3.4%, MOS +3.3%, SPG +2.8%, KKR +2.3%, DD +2.2%, WLTW +2.2%, OPCH +2.1%, ETRN +2%, IT +1.9%, IAA +1.9%, AQUA +1.7%, ZBRA +1.6%, PSXP +1.6%, INGR +1.4%, DISCA +1.4%, AME +1.3%, WMB +1.2%, WLK +1.2%, BLD +1.2%, SEE +1.2%, COP +1.1%, LGIH +1%, ESPR +0.9%, CMI +0.9%, MAR +0.8%
Other news:
- OTLK +43.4% (top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial)
- TBIO +29.6% (to be acquired by Sanofi (SNY) for $38.00 per share in cash)
- HOLI +19.4% (in process of evaluating offers from consortiums)
- GTBP +7.5% (preclinical results for GTB-5550 B7H3 TriKE)
- ARCT +6.7% (received approval for a Clinical Trial Application from the Singapore Health Sciences Authority to enable the advancement of two STARR mRNA vaccine candidates into the clinic)
- MRNS +6.3% (collaboration with Orion Corporation for commercialization of ganaxolone in Europe; submits NDA for the use of ganaxolone to treat seizures associated with CDKL5 deficiency disorder)
- PLXP +5% (3 SKUs of VAZALORE will be available in nearly 8,000 CVS stores later this month)
- FLR +4.4% (JV selected for Phase 2 of Interstate 35E expansion project in Texas)
- CECE +4% (authorizes $5 mln share repurchase program)
- GDRX +3.2% (GOCO announces exclusive Medicare agreement with GDRX)
- LPLA +2.1% (lowers advisory account minimums in OMP platform)
- GOCO +1.8% (GOCO announces exclusive Medicare agreement with GDRX)
- ABCL +1.5% (AbCellera Biologics & Tachyon collaborate to develop novel antibody therapeutic targeting TGF-31)
- ESEA +1.4% (announces a new time charter contract)
- ROAD +1.2% (acquries Good Hope Contracting and Daurity Springs Quarry)
- RRD +1.2% (responds to Chatham 13D filing)
- SEE +1.2% (to increase prices)
- ISBC +1.1% (ISBC receives approval from FDIC to acqurie certain branches of BHLB)
Analyst comments:
- BLMN +3.6% (upgraded to Outperform from Neutral at Credit Suisse)
- DXC +3.2% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- XPO +2% (upgraded to Buy from Neutral at Goldman)
- ABNB +1.7% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- PLNT +1.7% (upgraded to Buy from Hold at Stifel)
- HSBC +1.6% (upgraded to Buy from Hold at DBS Bank)
- WDAY +1.5% (upgraded to Overweight from Equal Weight at Barclays)